STERIS plc (STE) · Aug 5, 2026 · Company update

EPS beat modestly, but revenue and free-cash-flow outlook weakened

EPS beat modestly, but revenue and free-cash-flow outlook weakened

The quarter was better on earnings than on sales. Adjusted EPS was $2.59, above the published consensus of roughly $2.52, while revenue of $1.493 billion was slightly below the roughly $1.51 billion expectation.

MetricQ1 FY2027Q1 FY2026 / prior expectation
Revenue$1,492.7M (Financial Highlights)$1,391.1M; ~ $1.51B consensus
Adjusted diluted EPS$2.59 (Adjusted results reconciliation)$2.34; ~ $2.52 consensus
Constant-currency organic revenue growth6.2% (Organic growth table)FY2027 target: 6%–7%
Operating cash flow$367.1M (Cash Flow statement)$420.0M
Free cash flow$279.6M (Free Cash Flow table)$326.5M
FY2027 adjusted EPS guidance$11.10–$11.30 (FY2027 Outlook)Unchanged
FY2027 capital expenditures~$450M (FY2027 Outlook)Prior: ~$375M
FY2027 free-cash-flow guidance~$800M (FY2027 Outlook)Prior: ~$850M

Underlying demand remained solid, but the mix was uneven. Healthcare delivered the strongest contribution, with revenue up 8% and operating income up to $260.2 million from $235.5 million; recurring consumables and service revenue grew 9% and 10%, respectively (Segment results — Healthcare). Life Sciences also grew well, with revenue up 9% and constant-currency organic growth of 7.9% (Segment results — Life Sciences). AST revenue rose 6%, but its capital-equipment revenue fell 13%, making that segment's growth more dependent on services (Segment results — AST).

Management did not raise the earnings bar. Full-year revenue, organic-growth, and adjusted-EPS guidance were reiterated at 7%–8% reported revenue growth, 6%–7% constant-currency organic growth, and $11.10–$11.30 adjusted EPS (FY2027 Outlook). That makes the quarterly EPS beat helpful but not a clear change to the broader earnings picture.

Cash generation is the main negative surprise. First-quarter operating cash flow fell to $367.1 million from $420.0 million and free cash flow fell to $279.6 million from $326.5 million (Cash Flow statement; Free Cash Flow table). More importantly, the North Carolina chemistry facility investment lifted expected annual capital expenditures by $75 million, forcing free-cash-flow guidance down by $50 million to approximately $800 million (FY2027 Outlook). The company frames the investment as capacity and productivity improvement, but the near-term financial effect is higher spending and lower cash conversion.

The restructuring adds execution risk without changing adjusted EPS guidance today. STERIS expects $55 million–$70 million of pre-tax charges, including $40 million–$50 million of cash costs, spread through fiscal 2030 (Consolidation Plan). Because the charges will be excluded from adjusted earnings, they do not alter the stated EPS outlook; however, the long implementation timeline and facility closures mean the promised operational benefits remain unproven.

Net read: mixed rather than decisively positive. The adjusted-EPS beat and strong Healthcare performance were offset by a modest revenue shortfall, weaker quarterly cash flow, a lower free-cash-flow target, and newly quantified restructuring costs. The filing improves confidence in near-term margins and demand, but it does not lift the full-year earnings expectation.

Original filing on SEC EDGAR

More STERIS plc news

EPS beat modestly, but revenue and free-cash-flow outlook weakened | STE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.